Deans' stroke musings: Good Cholesterol May Not Lower Heart Risk, Study Suggests

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, May 17, 2012

Good Cholesterol May Not Lower Heart Risk, Study Suggests

More news to confound your doctor with. Ask away.
http://www.bloomberg.com/news/2012-05-17/good-cholesterol-may-not-lower-heart-risk-study-suggests.html
Raising good cholesterol, a goal pursued by Merck & Co. and Eli Lilly & Co. (LLY) as the next milestone in cardiac care, may not cut heart attack risk, says a study that challenges the development of drugs that may generate billions of dollars in sales.
The report, in the U.K. medical journal The Lancet, found that people with a genetic condition that causes high HDL have the same heart-attack risk as the general population. The results come from a computer analysis of 20 studies.

Scientists have said HDL works by sweeping the bad form of the fatty substance known as LDL, or bad cholesterol, out of arteries, reducing clogs. Photographer: Paul J. Richards/AFP/Getty Images

The authors suggested the link found earlier between good cholesterol and lower heart risk may come from more subtle lifestyle factors tied to higher HDL levels. If so, it brings into question the development of medicines such as Merck’s anacetrapib, an HDL booster that Tony Butler, a Barclay’s Capital analyst in New York, said on May 7 may generate $4 billion in peak revenue once approved.
“This will have a sobering effect, it would have to,” said John LaMattina, a senior partner at PureTech Ventures and former head of research and development at Pfizer Inc. (PFE) “HDL has always been a controversial area. You have a question that you have to be willing to commit over a billion dollars in order to get the answer, and that is a very daunting commitment.”
Scientists have said HDL works by sweeping the bad form of the fatty substance known as LDL, or bad cholesterol, out of arteries, reducing clogs. The Lancet study analyzed 20,913 heart attack cases and 95,047 control subjects, the report said.

The rest at the link.